Amicus Therapeutics’ Triumphant Surge: What the Future Holds for This Biotech Pioneer
Amicus Therapeutics achieved a remarkable 32% revenue surge, reaching $528 million in 2024, primarily driven by Galafold. Galafold soared to $458 million due to strong patient uptake and strategic market expansion. POMBILITI and OPFOLDA generated over $70 million in their first year,
